.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Merck
Johnson and Johnson
Queensland Health
Boehringer Ingelheim
Cipla
Mallinckrodt
Dow
Medtronic
US Department of Justice

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,132,239

« Back to Dashboard

Which drugs does patent 9,132,239 protect, and when does it expire?


Patent 9,132,239 protects NORDITROPIN FLEXPRO, LEVEMIR FLEXTOUCH, NOVOLOG FLEXTOUCH, FIASP FLEXTOUCH, RYZODEG 70/30, SAXENDA, TRESIBA, and XULTOPHY 100/3.6, and is included in eight NDAs.

This patent has eleven patent family members in ten countries.

Summary for Patent: 9,132,239

Title:Dial-down mechanism for wind-up pen
Abstract: The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm (21) engaging a ring element (10) and a reset element (30) which acts on a knob located on the periphery of the ratchet arm (21) to move the ratchet arm (21) out of engagement with the ring element (10) in order to allow the set dose to be reduced.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK), Radmer; Bo (Hillerod, DK), Enggaard; Christian Peter (Vejby, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/124,995
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncLEVEMIR FLEXTOUCHinsulin detemir recombinantINJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNOVOLOG FLEXTOUCHinsulin aspart recombinantINJECTABLE;SUBCUTANEOUS020986-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncFIASP FLEXTOUCHinsulin aspart recombinantSOLUTION;SUBCUTANEOUS208751-002Sep 29, 2017RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncRYZODEG 70/30insulin aspart; insulin degludecSOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,132,239

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08167547Oct 24, 2008
PCT Information
PCT FiledOctober 21, 2009PCT Application Number:PCT/EP2009/063801
PCT Publication Date:April 29, 2010PCT Publication Number: WO2010/046394

International Patent Family for Patent: 9,132,239

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2738877► Subscribe
China102196835► Subscribe
Denmark2373361► Subscribe
European Patent Office2373361► Subscribe
Spain2394556► Subscribe
Japan2012506273► Subscribe
Australia2009306387► Subscribe
BrazilPI0919925► Subscribe
Japan5558477► Subscribe
Russian Federation2011118236► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Dow
Accenture
Covington
Cipla
Fuji
Baxter
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot